Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. September 2019 16:05 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

SANTA MONICA, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
17. September 2019 08:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Strengthens Management Team with Appointments of Chief Commercial Officer and General Counsel

SANTA MONICA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
27. August 2019 16:30 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences

SANTA MONICA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
08. August 2019 16:05 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
30. Juli 2019 16:30 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, August 8

SANTA MONICA, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
23. Juli 2019 08:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of Acute Cannabinoid Overdose

SANTA MONICA, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today...
09. Mai 2019 16:05 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
30. April 2019 16:05 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, May 9

SANTA MONICA, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
08. April 2019 08:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose

SANTA MONICA, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today...
03. April 2019 08:00 ET | Quelle: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder

SANTA MONICA, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today...

Vorherige Seite

Nächste Seite